Each month biotechnology, pharmaceutical and academic partners, large and small, working on treatments and a cure for myotonic dystrophy sit down with our community to share their progress and answer your questions.
The Avidity Biosciences team presents, "MARINA Data: A Preliminary Assessment from the Phase 1/2 Clinical Trial for DM1" on December 16, 2022. Click here to read their recent press release and open letter to the DM Community.
Click here to learn more about Avidity Biosciences.
- Kelly DiTrapani, RN, BSN, BA
Avidity Biosciences, Vice President of Medical Affairs
- Nicholas Johnson, MD, MSCI, FAAN
Virginia Commonwealth University, MARINA Principal Investigator
- Mike Flanagan, PhD
Avidity Biosciences, Chief Technical Officer
Click here to find all our recorded Meet the DM Drug Developer sessions.